Literature DB >> 1328205

Kinetic model of the epidermal growth factor (EGF) receptor tyrosine kinase and a possible mechanism of its activation by EGF.

I Posner1, M Engel, A Levitzki.   

Abstract

The tyrosine kinase activity of the epidermal growth factor receptor (EGFR-TK) was determined at varying poly-Glu6Ala3Tyr1 (GAT) or [Val5]-angiotensin II (AT) and constant ATP concentrations and vice versa. With GAT as substrate, double reciprocal plots intersected practically on the abscissa following EGFR-TK pre-activation with EGF, but below the abscissa without EGF pre-activation. The EGFR-TK inhibitors App(NH)p (5'-adenylyl-beta, gamma-imidodiphosphate) and ADP were competitive with ATP and noncompetitive with GAT. Four families of 1/v vs. 1/[ATP] plots, constructed at different fixed concentrations of ADP and a different constant concentration of GAT for each family, yielded Slope1/ATP replots which intersected to the left of the ordinate and below the abscissa. GAT and AT, as cosubstrates, were competitive with each other and noncompetitive with ATP; 1/v vs. 1/[GAT] or 1/[AT] plots were hyperbolic and reached horizontal asymptotes when v was expressed as the rate of common product formation. All data were subjected to computer best-fit analysis by a program written especially for this purpose. We conclude that (i) the EGFR-TK reaction follows a Sequential Bi-Bi Rapid Equilibrium Random mechanism, and (ii) EGF induces conformational changes in the EGFR-TK active center which lead to marked decreases in the apparent dissociation constants of both substrates of the kinase reaction and a concomitant increase in initial velocities and Vmax (apparent).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328205

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands.

Authors:  S Maliartchouk; H U Saragovi
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

2.  Steady-state kinetic mechanism of PDK1.

Authors:  Xinxin Gao; Thomas K Harris
Journal:  J Biol Chem       Date:  2006-05-31       Impact factor: 5.157

3.  Conformational changes accompany phosphorylation of the epidermal growth factor receptor C-terminal domain.

Authors:  Nam Y Lee; John G Koland
Journal:  Protein Sci       Date:  2005-09-30       Impact factor: 6.725

4.  Structure and dynamics of the epidermal growth factor receptor C-terminal phosphorylation domain.

Authors:  Nam Y Lee; Theodore L Hazlett; John G Koland
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

Review 5.  Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.

Authors:  A E Wakeling; A J Barker; D H Davies; D S Brown; L R Green; S A Cartlidge; J R Woodburn
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 6.  The ErbB kinase domain: structural perspectives into kinase activation and inhibition.

Authors:  Ron Bose; Xuewu Zhang
Journal:  Exp Cell Res       Date:  2008-08-15       Impact factor: 3.905

7.  Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation.

Authors:  Payal R Sheth; John L Hays; Lisa A Elferink; Stanley J Watowich
Journal:  Biochemistry       Date:  2008-03-07       Impact factor: 3.162

Review 8.  Tyrosine kinase inhibitors: a clinical perspective.

Authors:  Sanjay Goel; Sridhar Mani; Roman Perez-Soler
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.945

9.  Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation.

Authors:  John G Koland
Journal:  PLoS Comput Biol       Date:  2014-01-16       Impact factor: 4.475

10.  Quantitative characterization of cellular membrane-receptor heterogeneity through statistical and computational modeling.

Authors:  Jared C Weddell; P I Imoukhuede
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.